Welcome to our dedicated page for Scinai Immunotherapeutics Ltd. news (Ticker: SCNI), a resource for investors and traders seeking the latest updates and insights on Scinai Immunotherapeutics Ltd. stock.
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biopharmaceutical company that regularly publishes updates on its dual business model: development of inflammation and immunology (I&I) biologics and operation of a boutique biologics CDMO under the Scinai Bioservices brand. The news flow around SCNI reflects both scientific progress and the evolution of its contract development and manufacturing activities.
Company press releases highlight several recurring themes. On the R&D side, Scinai reports advances in its NanoAb-based I&I pipeline, including anti‑IL‑17 programs for psoriasis and additional NanoAbs arising from collaborations with the Max Planck Society and University Medical Center Göttingen. News items also cover the PC111 program, a first‑in‑class human anti-Fas Ligand monoclonal antibody being developed for severe dermatological conditions such as pemphigus vulgaris and SJS/TEN through an option agreement to acquire Pincell Srl.
On the CDMO side, Scinai’s news frequently addresses growth in Scinai Bioservices, including revenue contributions from its U.S. subsidiary, new service orders, and infrastructure expansions such as an Israel Innovation Authority grant to fund an advanced sterile fill‑and‑finish system. These updates provide context on how the company is expanding its role as a boutique CDMO serving early-stage biotech clients in Israel, the United States, and Europe.
Investors and industry observers can also find announcements on equity financing arrangements, grant applications and outcomes, participation in sector conferences, and governance or cost-structure changes reported via Form 6‑K. This news page aggregates those releases so readers can follow SCNI’s financial results, pipeline milestones, CDMO capacity developments, and strategic transactions over time.
Scinai Immunotherapeutics (NASDAQ: SCNI) reported its H1 2025 financial results, showcasing growth in its CDMO business. Revenues reached $773,000, up from $284,000 in H1 2024, while net loss decreased to $4.13 million from $4.48 million.
The company strengthened its balance sheet through a $4.2 million raise via its Standby Equity Purchase Agreement. CDMO operations generated $1.0 million in total orders for 2025, with $850,000 already invoiced. R&D initiatives include advancing anti-IL-17 NanoAb programs, pursuing EU grant funding, and exploring an acquisition opportunity with PinCell srl.
Scinai Immunotherapeutics (NASDAQ:SCNI) announced a new peer-reviewed publication validating PC111, their first-in-class human anti-Fas Ligand monoclonal antibody, as a potential disease-modifying therapy for pemphigus and SJS/TEN. The research, published in the Journal of Dermatological Treatment, demonstrates PC111's ability to prevent blister formation across multiple study models.
The study confirms PC111's unique non-immunosuppressive mechanism, acting locally at the keratinocyte level. The treatment represents a market opportunity exceeding $1 billion annually. Scinai and Pincell plan to advance PC111 through IND-enabling studies, with potential market entry in 3-4 years. The program may receive up to 80% cost coverage through a €15 million FENG grant, pending Q3 2025 decision.
Scinai Immunotherapeutics (NASDAQ:SCNI) announces that Dr. Roberta Lotti from Pincell Srl has received the prestigious "Oscar of Italian Dermatology" for her groundbreaking research on PC111, a first-in-class anti-Fas Ligand monoclonal antibody. The award recognizes Dr. Lotti's paper demonstrating PC111's efficacy in treating pemphigus through a novel, non-immunosuppressive approach.
PC111, which Scinai has rights to through a strategic option agreement to acquire Pincell srl, targets soluble Fas Ligand (sFasL) in Pemphigus Vulgaris (PV) and Stevens-Johnson/Toxic Epidermal Necrolysis (SJS/TEN). The research confirms that PC111 blocks blister formation by inhibiting keratinocyte apoptosis, representing a potential paradigm shift from current immunosuppressive treatments.
Scinai Immunotherapeutics (NASDAQ: SCNI) announced a webinar scheduled for May 7th, 2025, at 11:30 AM EST to discuss PC111, a novel monoclonal antibody targeting soluble Fas ligand (sFasL) for treating Pemphigus Vulgaris and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN). The webinar follows Scinai's March 27th binding option agreement to acquire Italian biotech Pincell srl.
The company's Polish subsidiary has submitted a €12 million grant application under the European Funds for Modern Economy program, with a decision expected in Q3 2025. The webinar will feature key executives and medical experts who will discuss the diseases, current treatments, and PC111's development plan.
Scinai Immunotherapeutics (Nasdaq: SCNI) has entered a binding option agreement to acquire Italian biotech company Pincell srl. The acquisition centers around PC111, a monoclonal antibody in development for treating severe dermatological conditions including Pemphigus, Steven Johnson's Syndrome (SJS), and Toxic Epidermal Necrolysis (TEN).
Key developments include:
- PC111 has received Orphan Drug Designation in Pemphigus from the European Medicines Agency
- Plans to file for FDA Orphan Drug and Breakthrough Designation for both Pemphigus and SJS/TEN
- Scinai's Polish subsidiary has submitted a €12 million grant application under the European Funds for Modern Economy program
- Grant decision expected by mid-July/beginning of August 2025
Scinai Immunotherapeutics (NASDAQ: SCNI) has announced its participation in the BIO-Europe Spring 2025 conference in Milan, Italy, from March 17-19. The company's leadership team, including CEO Amir Reichman, CTO Dr. Dalit Weinstein-Fischer, and Business Development Director Solomon Gahtan, will engage with various stakeholders.
The company will focus on three main objectives: showcasing their inflammation and immunology (I&I) product pipeline to potential pharma partners interested in co-development or licensing of NanoAbs, presenting their end-to-end biologics CDMO services, and meeting with institutional and private investors. Interested parties can schedule meetings through the conference partnering platform or by emailing bd@scinai.com. Scinai will maintain presence at exhibitor booth #22 throughout the conference.